Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agonist, in patients with COPD: A 28-day randomised, placebo controlled clinical trial - Concepedia

Concepedia

Publication | Open Access

Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agonist, in patients with COPD: A 28-day randomised, placebo controlled clinical trial

DOI Full Paper Access

81

Citations

15

References

2006

Year

Jutta Beier, Pascal Chanez, Jean‐Benoît Martinot, A. J. M. Schreurs, Ružena Tkáčová, Weibin Bao, Damon Jack, Mark Higgins

Pulmonary Pharmacology & Therapeutics

Novel Once-daily β2-AgonistMedicineClinical TrialsPulmonary PharmacologyPulmonary MedicinePharmacotherapyPharmacologyPulmonary Disease

References

	Year	Citations

Page 1